Janus-like role of fibroblast growth factor 2 in arteriosclerotic coronary artery disease: Atherogenesis and angiogenesis

Atherosclerosis

Volumn 229, Issue 1, 2013, Pages 10-17

  Liu, Mi Hua ^a   Tang, Zhi Han ^a   Li, Guo Hua ^a   Qu, Shun Lin ^a   Zhang, Yuan ^a   Ren, Zhong ^a   Liu, Lu Shan ^a   Jiang, Zhi Sheng ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Angiogenesis; Atherosclerosis; Coronary artery disease; Fibroblast growth factor 2

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1;

ANGIOGENESIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; CELL MIGRATION; CELL PROLIFERATION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; HEART FUNCTION; HEART MUSCLE FIBROSIS; HEART MUSCLE PERFUSION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; INTRACELLULAR SIGNALING; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SMOOTH MUSCLE FIBER; THORACOTOMY; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

CORONARY ARTERY DISEASE; FIBROBLAST GROWTH FACTOR 2; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 84879414535     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.03.013     Document Type: Review

References (91)

1. Weber C., Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011, 17:1410-1422.
2. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. NEngl J Med 2005, 352:1685-1695.
3. Vaccarino V., Badimon L., Corti R., et al. Ischaemic heart disease in women: are there sex differences in pathophysiology and risk factors? position paper from the working group on coronary pathophysiology and microcirculation of the European Society of Cardiology. Cardiovasc Res 2011, 90:9-17.
4. Kirtane A.J., Pinto D.S., Moses J.W. Comparative effectiveness of revascularization strategies. NEngl J Med 2012, 367:476. author reply 477.
5. Itoh N., Ornitz D.M. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004, 563-569.
6. Vekony H., Ylstra B., Wilting S.M., et al. DNA copy number gains at loci of growth factors and their receptors in salivary gland adenoid cystic carcinoma. Clin Cancer Res 2007, 13:3133-3139.
7. Cabrita M.A., Christofori G. Sprouty proteins, masterminds of receptor tyrosine kinase signaling. Angiogenesis 2008, 11:53-62.
8. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010, 10:116-129.
9. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
10. Li D., Zhang C., Song F., et al. VEGF regulates FGF-2 and TGF-beta1 expression in injury endothelial cells and mediates smooth muscle cells proliferation and migration. Microvasc Res 2009, 77:134-142.
11. Hughes S.E. Localisation and differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal and atherosclerotic human arteries. Cardiovasc Res 1996, 32:557-569.
12. Zhang X., Ibrahimi O.A., Olsen S.K., et al. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. JBiol Chem 2006, 281:15694-15700.
13. Rodriguez-Campos A., Ruiz-Enriquez P., Faraudo S., et al. Mitogen-induced p53 downregulation precedes vascular smooth muscle cell migration from healthy tunica media and proliferation. Arterioscler Thromb Vasc Biol 2001, 21:214-219.
14. Brogi E., Winkles J.A., Underwood R., et al. Distinct patterns of expression of fibroblast growth factors and their receptors in human atheroma and nonatherosclerotic arteries. Association of acidic FGF with plaque microvessels and macrophages. JClin Invest 1993, 92:2408-2418.
15. Lindner V. Role of basic fibroblast growth factor and platelet-derived growth factor (B-chain) in neointima formation after arterial injury. ZKardiol 1995, 84(Suppl. 4):137-144.
16. Barillari G., Iovane A., Bonuglia M., et al. Fibroblast growth factor-2 transiently activates the p53 oncosuppressor protein in human primary vascular smooth muscle cells: implications for atherogenesis. Atherosclerosis 2010, 210:400-406.
17. Skjot-Arkil H., Barascuk N., Register T., et al. Macrophage-mediated proteolytic remodeling of the extracellular matrix in atherosclerosis results in neoepitopes: a potential new class of biochemical markers. Assay Drug Dev Technol 2010, 8:542-552.
18. Kenagy R.D., Hart C.E., Stetler-Stevenson W.G., et al. Primate smooth muscle cell migration from aortic explants is mediated by endogenous platelet-derived growth factor and basic fibroblast growth factor acting through matrix metalloproteinases 2 and 9. Circulation 1997, 96:3555-3560.
19. Chan J., Prado-Lourenco L., Khachigian L.M., et al. TRAIL promotes VSMC proliferation and neointima formation in a FGF-2-, Sp1 phosphorylation-, and NFkappaB-dependent manner. Circ Res 2010, 106:1061-1071.
20. Raines E.W. The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease. Int J Exp Pathol 2000, 81:173-182.
21. Gomez D., Owens G.K. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res 2012, 95:156-164.
22. Owens G.K. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 1995, 75:487-517.
23. Wamhoff B.R., Bowles D.K., Owens G.K. Excitation-transcription coupling in arterial smooth muscle. Circ Res 2006, 98:868-878.
24. Chen P.Y., Simons M., Friesel R. FRS2 via fibroblast growth factor receptor 1 is required for platelet-derived growth factor receptor beta-mediated regulation of vascular smooth muscle marker gene expression. JBiol Chem 2009, 284:15980-15992.
25. Liang Q.H., Jiang Y., Zhu X., et al. Ghrelin attenuates the osteoblastic differentiation of vascular smooth muscle cells through the ERK pathway. PLoS One 2012, 7:e33126.
26. Nakahara T., Sato H., Shimizu T., et al. Fibroblast growth factor-2 induces osteogenic differentiation through a Runx2 activation in vascular smooth muscle cells. Biochem Biophys Res Commun 2010, 394:243-248.
27. Busse R., Fleming I. Endothelial dysfunction in atherosclerosis. JVasc Res 1996, 33:181-194.
28. Tsuboi R., Sato Y., Rifkin D.B. Correlation of cell migration, cell invasion, receptor number, proteinase production, and basic fibroblast growth factor levels in endothelial cells. JCell Biol 1990, 110:511-517.
29. Murakami M., Nguyen L.T., Zhuang Z.W., et al. The FGF system has a key role in regulating vascular integrity. JClin Invest 2008, 118:3355-3366.
30. Matsunaga S., Okigaki M., Takeda M., et al. Endothelium-targeted overexpression of constitutively active FGF receptor induces cardioprotection in mice myocardial infarction. JMol Cell Cardiol 2009, 46:663-673.
31. Six I., Mouquet F., Corseaux D., et al. Protective effects of basic fibroblast growth factor in early atherosclerosis. Growth Factor 2004, 22:157-167.
32. Ananyeva N., Tjurmin A., Saenko E., et al. Low density lipoproteins interact with acidic fibroblast growth factor and modify its function. Arterioscler Thromb Vasc Biol 2003, 23:601-607.
33. Che J., Okigaki M., Takahashi T., et al. Endothelial FGF receptor signaling accelerates atherosclerosis. Am J Physiol Heart Circ Physiol 2011, 300:H154-H161.
34. Raj T., Kanellakis P., Pomilio G., et al. Inhibition of fibroblast growth factor receptor signaling attenuates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2006, 26:1845-1851.
35. Williams J.K. Endothelial FGF receptor signaling: angiogenic versus atherogenic effects. Am J Physiol Heart Circ Physiol 2011, 300:H27-H28.
36. Sapienza P., di Marzo L., Borrelli V., et al. Basic fibroblast growth factor mediates carotid plaque instability through metalloproteinase-2 and -9 expression. Eur J Vasc Endovasc Surg 2004, 28:89-97.
37. Khurana R., Zhuang Z., Bhardwaj S., et al. Angiogenesis-dependent and independent phases of intimal hyperplasia. Circulation 2004, 110:2436-2443.
38. Neschis D.G., Safford S.D., Hanna A.K., et al. Antisense basic fibroblast growth factor gene transfer reduces early intimal thickening in a rabbit femoral artery balloon injury model. JVasc Surg 1998, 27:126-134.
39. Cuevas P., Gonzalez A.M., Carceller F., et al. Vascular response to basic fibroblast growth factor when infused onto the normal adventitia or into the injured media of the rat carotid artery. Circ Res 1991, 69:360-369.
40. Tanaka K., Nagata D., Hirata Y., et al. Augmented angiogenesis in adventitia promotes growth of atherosclerotic plaque in apolipoprotein E-deficient mice. Atherosclerosis 2011, 215:366-373.
41. Hagg S., Salehpour M., Noori P., et al. Carotid plaque age is a feature of plaque stability inversely related to levels of plasma insulin. PLoS One 2011, 6:e18248.
42. Wong K.K., Thavornpattanapong P., Cheung S.C., et al. Effect of calcification on the mechanical stability of plaque based on a three-dimensional carotid bifurcation model. BMC Cardiovasc Disord 2012, 12:7.
43. Hasdai D., Barak V., Leibovitz E., et al. Serum basic fibroblast growth factor levels in patients with ischaemic heart disease. Int J Cardiol 1997, 59:133-138.
44. Lindner V., Reidy M.A. Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries. An en face study. Circ Res 1993, 73:589-595.
45. Sigala F., Savvari P., Liontos M., et al. Increased expression of bFGF is associated with carotid atherosclerotic plaques instability engaging the NF-kappaB pathway. JCell Mol Med 2010.
46. Iwashina M., Shichiri M., Marumo F., et al. Transfection of inducible nitric oxide synthase gene causes apoptosis in vascular smooth muscle cells. Circulation 1998, 98:1212-1218.
47. Popowich D.A., Vavra A.K., Walsh C.P., et al. Regulation of reactive oxygen species by p53: implications for nitric oxide-mediated apoptosis. Am J Physiol Heart Circ Physiol 2010, 298:H2192-H2200.
48. Heo S.H., Cho C.H., Kim H.O., et al. Plaque rupture is a determinant of vascular events in carotid artery atherosclerotic disease: involvement of matrix metalloproteinases 2 and 9. JClin Neurol 2011, 7:69-76.
49. Ahn A., Frishman W.H., Gutwein A., et al. Therapeutic angiogenesis: a new treatment approach for ischaemic heart disease-part II. Cardiol Rev 2008, 16:219-229.
50. Nessa A., Latif S.A., Siddiqui N.I., et al. Angiogenesis-a novel therapeutic approach for ischaemic heart disease. Mymensingh Med J 2009, 18:264-272.
51. Schaper W. Collateral circulation: past and present. Basic Res Cardiol 2009, 104:5-21.
52. Schultz J.E., Witt S.A., Nieman M.L., et al. Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. JClin Invest 1999, 104:709-719.
53. Virag J.A., Rolle M.L., Reece J., et al. Fibroblast growth factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular function. Am J Pathol 2007, 171:1431-1440.
54. Zhao T., Zhao W., Chen Y., et al. Acidic and basic fibroblast growth factors involved in cardiac angiogenesis following infarction. Int J Cardiol 2011, 152:307-313.
55. Banquet S., Gomez E., Nicol L., et al. Arteriogenic therapy by intramyocardial sustained delivery of a novel growth factor combination prevents chronic heart failure. Circulation 2011, 124:1059-1069.
56. Lu H., Xu X., Zhang M., et al. Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs. Proc Natl Acad Sci U S A 2007, 104:12140-12145.
57. Tengood J.E., Ridenour R., Brodsky R., et al. Sequential delivery of basic fibroblast growth factor and platelet-derived growth factor for angiogenesis. Tissue Eng Part A 2011, 17:1181-1189.
58. Chow L.W., Bitton R., Webber M.J., et al. Abioactive self-assembled membrane to promote angiogenesis. Biomaterials 2011, 32:1574-1582.
59. Nie S.P., Wang X., Qiao S.B., et al. Improved myocardial perfusion and cardiac function by controlled-release basic fibroblast growth factor using fibrin glue in a canine infarct model. JZhejiang Univ Sci B 2010, 11:895-904.
60. Chu H., Gao J., Chen C.W., et al. Injectable fibroblast growth factor-2 coacervate for persistent angiogenesis. Proc Natl Acad Sci U S A 2011, 108:13444-13449.
61. Kim M.S., Bhang S.H., Yang H.S., et al. Development of functional fibrous matrices for the controlled release of basic fibroblast growth factor to improve therapeutic angiogenesis. Tissue Eng Part A 2010, 16:2999-3010.
62. Tang D.W., Yu S.H., Ho Y.C., et al. Heparinized chitosan/poly(gamma-glutamic acid) nanoparticles for multi-functional delivery of fibroblast growth factor and heparin. Biomaterials 2010, 31:9320-9332.
63. Garbern J.C., Minami E., Stayton P.S., et al. Delivery of basic fibroblast growth factor with a pH-responsive, injectable hydrogel to improve angiogenesis in infarcted myocardium. Biomaterials 2011, 32:2407-2416.
64. Detillieux K.A., Sheikh F., Kardami E., et al. Biological activities of fibroblast growth factor-2 in the adult myocardium. Cardiovasc Res 2003, 57:8-19.
65. Kardami E., Liu L., Doble B.W. Basic fibroblast growth factor in cultured cardiac myocytes. Ann N Y Acad Sci 1991, 638:244-255.
66. Liao S., Porter D., Scott A., et al. The cardioprotective effect of the low molecular weight isoform of fibroblast growth factor-2: the role of JNK signaling. JMol Cell Cardiol 2007, 42:106-120.
67. Jiang Z.S., Padua R.R., Ju H., et al. Acute protection of ischaemic heart by FGF-2: involvement of FGF-2 receptors and protein kinase C. Am J Physiol Heart Circ Physiol 2002, 282:H1071-H1080.
68. Jiang Z. Non-angiogenic FGF-2 protects the ischemic heart from injury, in the presence or absence of reperfusion. Cardiovasc Res 2004, 62:154-166.
69. Jiang Z.S., Wen G.B., Tang Z.H., et al. High molecular weight FGF-2 promotes postconditioning-like cardioprotection linked to activation of protein kinase C isoforms, as well as Akt and p70 S6 kinases. [corrected]. Can J Physiol Pharmacol 2009, 87:798-804.
70. House S.L., Bolte C., Zhou M., et al. Cardiac-specific overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and infarction in a murine model of low-flow ischaemia. Circulation 2003, 108:3140-3148.
71. House S.L., Branch K., Newman G., et al. Cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2 is mediated by the MAPK cascade. Am J Physiol Heart Circ Physiol 2005, 289:H2167-H2175.
72. House S.L., Melhorn S.J., Newman G., et al. The protein kinase C pathway mediates cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2. Am J Physiol Heart Circ Physiol 2007, 293:H354-H365.
73. Xiao J., Lv Y., Lin S., et al. Cardiac protection by basic fibroblast growth factor from ischaemia/reperfusion-induced injury in diabetic rats. Biol Pharm Bull 2010, 33:444-449.
74. Manning J.R., Carpenter G., Porter D.R., et al. Fibroblast growth factor-2-induced cardioprotection against myocardial infarction occurs via the interplay between nitric oxide, protein kinase signaling, and ATP-sensitive potassium channels. Growth Factor 2012.
75. Schumacher B., Stegmann T., Pecher P. The stimulation of neoangiogenesis in the ischemic human heart by the growth factor FGF: first clinical results. JCardiovasc Surg (Torino) 1998, 39:783-789.
76. Laham R.J., Sellke F.W., Edelman E.R., et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999, 100:1865-1871.
77. Sellke F.W., Laham R.J., Edelman E.R., et al. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg 1998, 65:1540-1544.
78. Ruel M., Laham R.J., Parker J.A., et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. JThorac Cardiovasc Surg 2002, 124:28-34.
79. Laham R.J., Chronos N.A., Pike M., et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. JAm Coll Cardiol 2000, 36:2132-2139.
80. Unger E.F., Goncalves L., Epstein S.E., et al. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am J Cardiol 2000, 85:1414-1419.
81. Simons M., Annex B.H., Laham R.J., et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002, 105:788-793.
82. Katayama Y., Takaji K., Shao Z.Q., et al. The value of angiogenic therapy with intramyocardial administration of basic fibroblast growth factor to treat severe coronary artery disease. Ann Thorac Cardiovasc Surg 2010, 16:174-180.
83. Kukula K., Chojnowska L., Dabrowski M., et al. Intramyocardial plasmid-encoding human vascular endothelial growth factor A165/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD). Am Heart J 2011, 161:581-589.
84. Epstein S.E., Stabile E., Kinnaird T., et al. Janus phenomenon: the interrelated tradeoffs inherent in therapies designed to enhance collateral formation and those designed to inhibit atherogenesis. Circulation 2004, 109:2826-2831.
85. Lin Y., Hogan W.J. Clinical application of mesenchymal stem cells in the treatment and prevention of graft-versus-host disease. Adv Hematol 2011, 2011. 427863.
86. Beitnes J.O., Gjesdal O., Lunde K., et al. Left ventricular systolic and diastolic function improve after acute myocardial infarction treated with acute percutaneous coronary intervention, but are not influenced by intracoronary injection of autologous mononuclear bone marrow cells: a 3 year serial echocardiographic sub-study of the randomized-controlled ASTAMI study. Eur J Echocardiogr 2011, 12:98-106.
87. Cho S.W., Kim I.K., Bhang S.H., et al. Combined therapy with human cord blood cell transplantation and basic fibroblast growth factor delivery for treatment of myocardial infarction. Eur J Heart Fail 2007, 9:974-985.
88. Strauer B.E., Steinhoff G. 10 years of intracoronary and intramyocardial bone marrow stem cell therapy of the heart: from the methodological origin to clinical practice. JAm Coll Cardiol 2011, 58:1095-1104.
89. Drinane M., Mollmark J., Zagorchev L., et al. The antiangiogenic activity of rPAI-1(23) inhibits vasa vasorum and growth of atherosclerotic plaque. Circ Res 2009, 104:337-345.
90. -/- microvascular endothelial cells requires prolonged activation of extracellular signal-regulated kinases-1 and -2 (ERK-1/2). JCell Biochem 2003, 90:1015-1025.
91. Udelson J.E., Dilsizian V., Laham R.J., et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 2000, 102:1605-1610.